Omega Diagnostics Group PLC - medical diagnostics company - Says the self-test usability study for the UK Rapid Test Consortium's Covid-19 lateral flow antibody test has concluded. The study was performed by Ulster University using 2,000 volunteers and completed over the weekend. The AbC-19 rapid test has already been CE-Marked for professional use. Omega said it remains on track to have production capacity in place this month to produce an initial 100,000 AbC-19 rapid test per week, scaling up to 200,000 tests per week capacity in October. "We're very pleased that the self-test usability study has completed and that we are progressing towards our goal of MHRA approval for self-test home use. We cannot give a timescale for when this might be achieved but we look forward to updating shareholders on further developments," said Chief Executive Colin King.
Current stock price: 67.59 pence
Year-to-date change: multiplied from 14.22p
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
